Dr. Torka is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
225 Summit Avenue
Montvale, NJ 07645
Summary
- Dr. Pallawi Torka is an oncologist in Buffalo, NY and is affiliated with Roswell Park Comprehensive Cancer Center. She received her medical degree from Jawaharlal Institute of Postgraduate Medical Education and Research and has been in practice 12 years. She also speaks multiple languages, including Hindi and Tamil. She specializes in hematologic oncology and is experienced in b-cell lymphomas, t-cell lymphomas, hodgkin's lymphoma, multiple myeloma, and t-cell and nk-cell lymphproliferative disorders.
Education & Training
SUNY Upstate Medical UniversityResidency, Internal Medicine, 2013
Jawaharlal Institute of Postgraduate Medical Education and ResearchClass of 2006, MBBS
University at BuffaloFellowship, Hematology and Medical Oncology
Certifications & Licensure
FL State Medical License 2023 - Present
NY State Medical License 2016 - 2026
CT State Medical License 2023 - 2025
NJ State Medical License 2022 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 182 citationsTriplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.Paul G Richardson, Susanna J Jacobus, Edie A Weller, Hani Hassoun, Sagar Lonial
The New England Journal of Medicine. 2022-07-14 - 4 citationsImpact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy.Reem Karmali, Rushad Machhi, Narendranath Epperla, Geoffrey Shouse, Jason Romancik
Blood Advances. 2024-05-28 - 104 citationsOutcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete RemissionDaniel J. Landsburg, Marissa K. Falkiewicz, Joseph Maly, Kristie A. Blum, Christina Howlett
Journal of Clinical Oncology. 2017-05-05
Abstracts/Posters
- Utility of Bone Marrow Biopsy in the Staging of T-Cell Lymphoma in the PET-CT EraPallawi Torka, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Early Complete Remission By Functional Imaging and Intensified Frontline Therapy Are Associated with an Improved Clinical Outcome in Patients with Newly Diagnosed T-Ce...Pallawi Torka, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- BCL-Xl Expression Is Druggable Biomarker Associated with a Poor Clinical Outcome in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Pallawi Torka, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Roswell Park Researchers Gear up for ASCO 2021 Annual MeetingJune 3rd, 2021
Cancer Centers Share the Steps They’re Taking to Keep Patients with Compromised Immune Systems Safe from the CoronavirusFebruary 11th, 2020
Immune Profiling in Non-Hodgkin Lymphoma Patients Receiving AHCTSeptember 5th, 2019
Committees
- Member, NCCN T-cell Lymphoma Committee
- Member, NCCN Primary Cutaneous B-cell Lymphoma Committee
Professional Memberships
- Member
- Member
Other Languages
- Hindi, Tamil
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
